AU2019211411B2 - MICA/B antibodies and methods of use - Google Patents

MICA/B antibodies and methods of use

Info

Publication number
AU2019211411B2
AU2019211411B2 AU2019211411A AU2019211411A AU2019211411B2 AU 2019211411 B2 AU2019211411 B2 AU 2019211411B2 AU 2019211411 A AU2019211411 A AU 2019211411A AU 2019211411 A AU2019211411 A AU 2019211411A AU 2019211411 B2 AU2019211411 B2 AU 2019211411B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019211411A
Other languages
English (en)
Other versions
AU2019211411A1 (en
Inventor
Justin Chapman
Xin Du
Neil Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cullinan Mica Corp
Original Assignee
Cullinan Mica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Mica Corp filed Critical Cullinan Mica Corp
Publication of AU2019211411A1 publication Critical patent/AU2019211411A1/en
Assigned to Cullinan Mica Corp. reassignment Cullinan Mica Corp. Amend patent request/document other than specification (104) Assignors: PDI THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2019211411B2 publication Critical patent/AU2019211411B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019211411A 2018-01-25 2019-01-24 MICA/B antibodies and methods of use Active AU2019211411B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621892P 2018-01-25 2018-01-25
US62/621,892 2018-01-25
PCT/US2019/015025 WO2019147863A2 (en) 2018-01-25 2019-01-24 Mica/b antibodies and methods of use

Publications (2)

Publication Number Publication Date
AU2019211411A1 AU2019211411A1 (en) 2020-08-20
AU2019211411B2 true AU2019211411B2 (en) 2025-11-27

Family

ID=67396240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019211411A Active AU2019211411B2 (en) 2018-01-25 2019-01-24 MICA/B antibodies and methods of use

Country Status (10)

Country Link
US (2) US20210047417A1 (https=)
EP (1) EP3743109A4 (https=)
JP (2) JP7458993B2 (https=)
KR (1) KR102731953B1 (https=)
CN (1) CN112566659A (https=)
AU (1) AU2019211411B2 (https=)
BR (1) BR112020015142A2 (https=)
IL (1) IL276187B1 (https=)
MX (1) MX2020007880A (https=)
WO (1) WO2019147863A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CA3186062A1 (en) * 2020-08-10 2022-02-17 Marion BENEZECH Cell surface mica and micb detection using antibodies
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
JP2025512137A (ja) * 2022-04-08 2025-04-16 ディーツーエム バイオセラピューティクス リミテッド 抗ｍｉｃａ／ｂ抗体及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) * 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof
WO2013049517A2 (en) * 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857116A1 (en) * 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
EP2970490A4 (en) * 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
KR102763121B1 (ko) * 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
US11780924B2 (en) * 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315287A1 (en) * 2011-05-31 2012-12-13 University Of Washington Through Its Center For Commercialization Mic-binding antibodies and methods of use thereof
WO2013049517A2 (en) * 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer

Also Published As

Publication number Publication date
JP2024038169A (ja) 2024-03-19
KR102731953B1 (ko) 2024-11-20
JP7458993B2 (ja) 2024-04-01
US20210047417A1 (en) 2021-02-18
RU2020128010A (ru) 2022-02-25
JP2021511387A (ja) 2021-05-06
WO2019147863A3 (en) 2019-10-24
MX2020007880A (es) 2021-05-14
EP3743109A4 (en) 2021-11-10
CA3089478A1 (en) 2019-08-01
BR112020015142A2 (pt) 2021-01-05
US20240067731A1 (en) 2024-02-29
KR20200115545A (ko) 2020-10-07
CN112566659A (zh) 2021-03-26
IL276187A (en) 2020-09-30
AU2019211411A1 (en) 2020-08-20
EP3743109A2 (en) 2020-12-02
WO2019147863A2 (en) 2019-08-01
IL276187B1 (en) 2026-02-01

Similar Documents

Publication Publication Date Title
AU2019211411B2 (en) MICA/B antibodies and methods of use
US20250034262A1 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
KR102422411B1 (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
CN111133004A (zh) 抗ctla-4抗体和其用途
WO2021093849A1 (en) A novel antibody against tigit
CA3089478C (en) Mica/b antibodies and methods of use
RU2821021C2 (ru) Антитела к mica/b и способы применения
RU2815101C2 (ru) Антитела против mica/b, блокирующие шеддинг mica/b, и способы их применения
KR102793781B1 (ko) Hla-g에 특이적으로 결합하는 항체 및 이의 용도
BR112021001808B1 (pt) Anticorpo monoclonal ou um fragmento de ligação ao antígeno, composição farmacêutica e uso do referido anticorpo monoclonal ou fragmento
JP2025525073A (ja) エフェクター機能が増強された抗ｍｉｃａ／ｂ抗体および使用方法
KR20250116642A (ko) 새로운 항-ctla4 항체
EP4720128A2 (en) Methods of treating cancer with anti-mica/b antibodies
JP2025503446A (ja) Ｔｉｇｉｔ抗体及びその用途
EA043281B1 (ru) Анти-cd47 антитела и их применение

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CULLINAN MICA CORP.

Free format text: FORMER NAME(S): PDI THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)